EDMONTON, Alberta, Aug. 27, 2013 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. today announced that the Company and its collaborators will be presenting 10 posters at the upcoming Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). These presentations provide details of the Company's investigational broad-spectrum beta-lactamase inhibitor, FPI-1465. FPI-1465 is undergoing pre-clinical testing as an adjunct to antibiotics for the treatment of patients with difficult-to-treat, resistant bacterial infections. ICAAC is being held in Denver, CO September 10-13, 2013.
The posters Fedora plans to present provide evidence showing that FPI-1465 increases the activity of ceftazidime, aztreonam, meropenem and other Gram-negative antibiotics, against bacteria that have developed resistance through the production of beta-lactamase enzymes. In a pair of in vitro studies, the combination of FPI-1465 with beta-lactam antibiotics was shown to significantly improve the activity of the antibiotic and resensitize the resistance bacteria to the antibiotic. Importantly, this increase in activity was measured against bacteria producing different classes of beta-lactamase including the metallo-family of enzymes, which has proven particularly challenging to address. These results were supported by an in vivo study of mice infected with a highly resistant strain of bacteria, in which the combination of FPI-1465 and a beta-lactam antibiotic resulted in significant reduction in bacteria counts measured 24-hours after infection.
The posters are as follows:
Tuesday, September 10, 12:00 pm - 2:00 pm
Poster Session: Promising Novel Beta-Lactamase Inhibitors, Exhibit
Hall A
Poster C1-059: "Mechanistic Studies of Inhibition of the CTX-M-15
and KPC-2 Serine Beta-Lactamases by FPI-1465 a beta-Lactamase
Inhibitors"
Thursday, September 12, 11:00 am - 1:00 pm
Poster Session: Beta-Lactams and Beta-Lactamase Inhibitors, Exhibit
Hall A
Poster F-1188: "Activity of Beta-Lactam Agents Tested in
Combination with a Novel Beta-Lactamase Inhibitor Compound
against Enterobacteriaceae Producing
Extended-spectrum Beta-Lactamase"
Thursday, September 12, 11:00 am - 1:00 pm
Poster Session: Beta-Lactams and Beta-Lactamase Inhibitors, Exhibit
Hall A
Poster F-1189: "Beta-lactam Activity Tested in Combination with a
Beta-lactamase Inhibitor Candidate
against Enterobacteriaceae Producing Class A, B
and D Carbapenemases"
Thursday, September 12, 11:00 am - 1:00 pm
Poster Session: Beta-Lactams and Beta-Lactamase Inhibitors, Exhibit
Hall A
Poster F-1190: "Design, Synthesis and Structure Activity
Relationship of Novel Substituted Amides Containing Diaza Bicyclic
Heterocyclic Compounds as Broad-spectrum Beta-lactamase
Inhibitors"
Thursday, September 12, 11:00 am - 1:00 pm
Poster Session: Beta-Lactams and Beta-Lactamase Inhibitors, Exhibit
Hall A
Poster F-1191: "Mechanistic Studies of FPI-1465 a Novel
Beta-lactamase Inhibitor"
Thursday, September 12, 11:00 am - 1:00 pm
Poster Session: Beta-Lactams and Beta-Lactamase Inhibitors, Exhibit
Hall A
Poster F-1192: "In vitro Checkerboard and Time
Kill Synergy Studies of a Novel Beta-lactamase Inhibitor (FPI-1465)
in Combination with Ceftazidime (CAZ)"
Thursday, September 12, 11:00 am - 1:00 pm
Poster Session: Beta-Lactams and Beta-Lactamase Inhibitors, Exhibit
Hall A
Poster F-1193: "Structural Insights into Inhibition of the CTX-M15
Serine Beta-Lactamase by FPI-1465"
Thursday, September 12, 11:00 am - 1:00 pm
Poster Session: Beta-Lactams and Beta-Lactamase Inhibitors, Exhibit
Hall A
Poster F-1194: "Efficacy of Ceftazidime (CAZ) in Combination
with FPI-1465 Novel Non-Beta-lactam Beta-lactamase Inhibitor in
Neutropenic Murine Thigh Model Caused by KPC-2
producing Klebsiella pneumoniae and VIM-1 &
KPC-3 producing Enterobacter cloacae"
Thursday, September 12, 11:00 am - 1:00 pm
Poster Session: Beta-Lactams and Beta-Lactamase Inhibitors, Exhibit
Hall A
Poster F-1195: "Pharmacokinetics of Novel Beta-lactamase
Inhibitor FPI-1465 in Mouse and Rat after Single Intravenous
Administration"
Thursday, September 12, 11:00 am - 1:00 pm
Poster Session: Beta-Lactams and Beta-Lactamase Inhibitors, Exhibit
Hall A
Poster F-1196: "Inhibition of CYP450s and In
Vitro and In Vivo Safety Profile of
FPI-1465 Novel non-Beta-lactam Beta‑lactamase Inhibitor"
The above posters will also be included in the oral Poster Summary Session on Tuesday, September 10 from 2:30 pm - 4:30 pm.
About Fedora Pharmaceuticals
Fedora Pharmaceuticals is developing a family of beta-lactamase inhibitors designed to have activity against pathogens containing all four classes of beta-lactamases. Beta-lactamases are enzymes produced by bacteria that destroy the ring structure common to beta-lactam antibiotics. This class of antibiotics, which includes penicillin derivatives, cephalosporins, monobactams and carbapenems, is estimated to comprise 65% of the antibiotics market worldwide. The beta-lactamase inhibitors under development at Fedora will be used in combination with various beta-lactam antibiotics to treat those antibiotic infections currently resistant to therapy. Fedora Pharmaceuticals is preparing to enter Investigational New Drug (IND)-enabling studies with its first beta-lactamase inhibitor candidate FPI-1465, and anticipates filing an IND application and initiating clinical studies in 2014. Fedora was founded in 2012 and is headquartered in Edmonton, Alberta, Canada. For more information on the company, please visit www.fedorapharma.com.